Psyence Biomedical Ltd

詳細情報 Psyence Biomedical Ltd 企業名

Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

企業情報

企業コードPBM

会社名Psyence Biomedical Ltd

上場日Dec 10, 2021

最高経営責任者「CEO」Dr. Neil Maresky

従業員数12

証券種類Ordinary Share

決算期末Dec 10

本社所在地121 Richmond Street West Penthouse

都市TORONTO

証券取引所NASDAQ Capital Market Consolidated

国Canada

郵便番号M5H 2K1

電話番号17744604171

ウェブサイト

企業コードPBM

上場日Dec 10, 2021

最高経営責任者「CEO」Dr. Neil Maresky

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Jody Aufrichtig

Chairman of the Board, Strategic Business Development Officer

--

Dr. Neil Maresky

Chief Executive Officer, Director

--

Mr. Warwick Corden-Lloyd

Chief Financial Officer

--

Mr. Marc Balkin

Independent Director

--

Mr. Christopher (Chris) Bull

Independent Director

--

Dr. Seth Feuerstein

Independent Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Jody Aufrichtig

Chairman of the Board, Strategic Business Development Officer

--

Dr. Neil Maresky

Chief Executive Officer, Director

--

Mr. Warwick Corden-Lloyd

Chief Financial Officer

--

Mr. Marc Balkin

Independent Director

--

Mr. Christopher (Chris) Bull

Independent Director

--

Dr. Seth Feuerstein

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Tue, Aug 19

株主統計

種類

株主統計

比率

Parallel Advisors, LLC

38.56%

Sabby Management, LLC

2.85%

White Lion Capital LLC

1.76%

AdvisorShares Investments, LLC

0.62%

BofA Global Research (US)

0.47%

他の

55.74%

株主統計

比率

Parallel Advisors, LLC

38.56%

Sabby Management, LLC

2.85%

White Lion Capital LLC

1.76%

AdvisorShares Investments, LLC

0.62%

BofA Global Research (US)

0.47%

他の

55.74%

種類

株主統計

比率

Investment Advisor

39.53%

Investment Advisor/Hedge Fund

2.85%

Venture Capital

1.83%

Corporation

0.48%

Research Firm

0.47%

他の

54.83%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

45

357.80K

50.17%

+181.11K

2025Q1

45

167.96K

26.60%

+69.68K

2024Q4

82

948.20K

24.27%

+587.08K

2024Q3

88

169.92K

15.90%

-186.51K

2024Q2

92

159.62K

36.84%

-203.47K

2024Q1

96

157.41K

35.61%

-211.56K

2023Q4

88

18.95K

16.18%

-253.66K

2023Q3

87

16.58K

55.18%

-252.44K

2023Q2

86

17.96K

50.97%

-264.02K

2023Q1

85

19.55K

55.14%

-329.89K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Sabby Management, LLC

32.21K

4.52%

+32.21K

--

Mar 31, 2025

White Lion Capital LLC

12.55K

1.76%

+12.55K

--

Dec 04, 2024

AdvisorShares Investments, LLC

4.45K

0.62%

+1.07K

+31.71%

Mar 31, 2025

Launchpad Ignition Holdings LLC

2.00K

0.28%

+2.00K

--

Mar 31, 2024

UBS Financial Services, Inc.

4.21K

0.59%

+2.62K

+164.01%

Mar 31, 2025

Tabula Rasa Ltd

1.45K

0.2%

-728.00

-33.47%

Mar 31, 2024

Stonehage Fleming Financial Services Holdings, Ltd.

562.00

0.08%

+562.00

--

Mar 31, 2025

Launchpad Capital Management Company, LLC

529.00

0.07%

+529.00

--

Mar 31, 2024

詳細を見る

4.760USD

Psyence Biomedical Ltd

4.760

概要

企業名

金融

分析